ライフサイエンスコーパス: denileukin diftitox

1 (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox).

2 g cells are depleted after multiple doses of denileukin diftitox.

3 NM) stage, histologic grade, and response to denileukin diftitox.

4 e susceptibility of T-cell leukemia cells to denileukin diftitox.

5 Injection of denileukin diftitox 1 day before vaccination enhanced an

6 ses of bexarotene (75 mg/day-300 mg/day) and denileukin diftitox (18 mcg/kg per day x 3 days every 21

7 Denileukin diftitox, a genetically engineered fusion pro

8 of two dose levels (9 or 18 microg/kg/d) of denileukin diftitox administered 5 consecutive days ever

9 Denileukin diftitox, also known as DAB(389)IL-2 or Ontak

10 results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and

11 toxin conjugate DAB(389)IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing t

12 Our results indicate that denileukin diftitox and other suppressor cell-depleting

13 tients receiving standard 5-day infusions of denileukin diftitox at 18 microg/kg/day.

14 Denileukin diftitox (DAB(389)IL-2), a fusion protein of

15 he efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceu

16 Denileukin diftitox (DD), a diphtheria toxin fragment IL

17 Denileukin diftitox (DD), a fusion protein comprising IL

18 estigate efficacy and safety of two doses of denileukin diftitox (DD; DAB(389)-interleukin-2 [IL-2]),

19 lus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denileukin), or pentostatin.

20 ted that a CD25(high) targeting immunotoxin (denileukin diftitox) depleted FoxP3(+) Treg cells, decre

21 However, denileukin diftitox (DT)-mediated Treg depletion improve

22 to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NH

23 sure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxica

24 In a pilot study (n = 15), denileukin diftitox, given as a single dose or repeated

25 0% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% parti

26 knowledge we report for the first time that denileukin diftitox has also dramatic effects regarding

27 Denileukin diftitox has been shown to be a useful and im

28 ected therapies, including the fusion toxin, denileukin diftitox, histone deacetylase inhibitors, and

29 depleted with the IL-2-toxin fusion protein (denileukin diftitox), HIV-1 infection is significantly i

30 We conducted a phase 1 study of denileukin diftitox in 30 patients with steroid refracto

31 We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculo

32 compartments and (2) the dose scheduling of denileukin diftitox in combination with a recombinant po

33 Evaluation of denileukin diftitox in combination with other agents may

34 Tregs were depleted by denileukin diftitox in humanized mice with chronic HIV-1

35 performed in vivo Treg depletion with Ontak (denileukin diftitox) in two SIVsab-infected controller m

36 Repeated injections of denileukin diftitox into female NOD mice at 12 wk of age

37 Denileukin diftitox is a fusion protein combining diphth

38 Meanwhile, denileukin diftitox is also used as an adjuvant in other

39 Denileukin diftitox is tolerable and has promising activ

40 These finding should be considered when denileukin diftitox is used for the treatment of patient

41 abetes, we demonstrate that the injection of denileukin diftitox leads to a dramatic development of t

42 Pentostatin, denileukin diftitox, mycophenolate mofetil, extracorpore

43 une responses, (3) the lack of inhibition by denileukin diftitox of host immune responses directed ag

44 In this study, we examined (1) the effect of denileukin diftitox on the deletion of Treg cells in var

45 murine model (1) the differential effects of denileukin diftitox on Treg cells in different cellular

46 Denileukin diftitox (Ontak), a recombinant fusion protei

47 Denileukin diftitox (Ontak), a recombinant protein compo

48 totherapy, and monoclonal antibodies such as denileukin diftitox or etanercept are reviewed.

49 These in vivo studies show that denileukin diftitox potentiates standard TB treatment in

50 nd combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxic

51 Denileukin diftitox seems to be effective in relapsed or

52 cells in the tumor grafts were depleted with denileukin diftitox, suggesting that tumor-specific T ce

53 after a single intraperitoneal injection of denileukin diftitox; the reduction was evident within 24

54 advanced CTCL and with clinical response to denileukin diftitox therapy.

55 p3(+) T cells could correct the defect after denileukin diftitox treatment.

56 Denileukin diftitox was administered intravenously at a

57 Denileukin diftitox was approved for the treatment of cu

58 ti-interleukin-2 and serum concentrations of denileukin diftitox were also measured.

59 and (4) the importance of dose scheduling of denileukin diftitox when used in combination with a vacc

60 compartments, (2) the advantage of combining denileukin diftitox with a vaccine to enhance antigen-sp